探討五種中藥單方處理非小細胞肺癌細胞株之效果

Investigation of the effect of five Chinese herbs in non-small cell lung carcinoma cell lines

沈志謙(Chih-Chien Shen)

指導教授 ： 謝秀梅

國立臺灣師範大學/理學院/生命科學研究所/碩士(2011年)

摘要

替代性療法近來在許多疾病中因為療效良好而備受關注；其好處
為除了可以有效的治療疾病之外，相較之下，其所帶來的毒性或是副
作用可能低於傳統的治療方式。多年以來，肺癌即是許多國家癌症死
亡的首位，而本研究主要的目的就是想要探討傳統的中草藥配方是否
對於非小細胞肺癌細胞株A549, NCI-H460, NCI-H520 具有抑制其生
長或是存活的效果。我們對細胞分別用了五種不同的中草藥
(HC1-HC5)作處理，再探討這些藥物是透過甚麼樣的機制去減低細胞
生長的情形。我們發現在五種中草藥方內有兩種中草藥HC3以及HC4
對於減低非小細胞肺癌細胞株之存活率有顯著的影響，但相同的劑量
對於正常細胞株MRC5 則沒有太大的影響。另外我們也以流式細胞
儀以及西方墨點轉漬的實驗進一步的探討藥物處理對於細胞週期的
表現影響，我們發現在藥物處理後細胞族群較多停滯在G1 以及G2
的現象，分析調節細胞週期的蛋白質表現結果也符合流式細胞儀看到
的結果。除此之外，我們也發現了A549 側群細胞(具有類癌幹細胞的
特性)的比例在經過藥物處理後有顯著降低的趨勢，我們也分析了間
質-表皮轉換(MET)的相關蛋白以進一步的解釋癌幹細胞可能的變化
機制。另外我們也觀測到癌細胞的轉移能力因為藥物的處理而降低。
由我們的分析結果顯示這些藥物也許有潛力可以應用於肺癌治療。

關鍵字

非小細胞肺癌 ； 中草藥 ； 癌幹細胞

並列摘要

Complementary Alternative Medicines (CAM) is attractive for its
therapeutic efficacy, and its less toxic effect in some diseases than
conventional treatments. Lung cancer has been the leading cause of
cancer death in many countries since a few years ago. In this study we
investigate if some of the Chinese Herbs have the therapeutic potential to
suppress the proliferation or survival rate of Non-Small Cell Lung
carcinoma (NSCLC) cell lines- A549, NCI-H460, and NCI-H520. We
used five different herbal complexes (HC1-5) to treat the cells, and
further investigated the mechanism that contribute to the reduction of cell
survival rate. Two of the five complexes, HC3 and HC4, reduced the
viability of cancer cells but not normal cells under the half maximal
inhibitory concentration (IC50) dosage. The results of flow cytometry
analysis indicated that these two HCs induced cell cycle arrested at G1
and G2 phases. We also confirmed this result by western blot analysis
showing that the expression levels of several cell-cycle regulators,
CDK4/6, cyclin D3 and cyclin B1were reduced after HC3 and HC4
treatment. In addition, side population (SP, which represented stem-like
cancer cells) was also reduced after the treatment. To further elucidate the
molecular mechanism, we examined the mesenchymal to epithelial
transition (MET) on cells after treatment. Furthermore, we also
performed the transwell assay to elucidate the cell migration ability after
treatment. The data showed that both of HCs decreased the migration
capacity of A549. In conclusion, these HCs may have potential to be
applied to the NSCLC therapy.

並列關鍵字

NSCLC ； Chinese herbs ； CSCs

參考文獻

　　王天駿。（2010）。以A549肺癌細胞株為模式篩選對非小細胞肺癌有治療潛力之中藥複方。國立臺灣師範大學研究所碩士論文。

Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA (2009) Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119:1438-1449.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988.

Biesalski HK, Bueno de Mesquita B, Chesson A, Chytil F, Grimble R, Hermus RJ, Kohrle J, Lotan R, Norpoth K, Pastorino U, Thurnham D (1998) European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin 48:167-176; discussion 164-166.

Blagosklonny MV, Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1:103-110.